大颗粒淋巴细胞白血病中STAT3激活与细胞因子信号及DNA高甲基化相关
该研究探讨LGLL中STAT3突变的功能效应,发现STAT3突变患者CD8+ T细胞高表达DNMT1并呈整体高甲基化;IL-6、IL-15和/或MCP-1细胞因子处理健康CD8+ T细胞可激活STAT3并上调表观调控因子、增加DNA甲基化和氧化应激;过表达STAT3Y640F和STAT3G618R突变体的KAI3 NK细胞再现类似结果;阿扎胞苷通过恢复SHP1表达抑制STAT3突变LGLL细胞的STAT3激活。
要点
- STAT3突变LGLL患者CD8+ T细胞DNMT1蛋白水平高且DNA整体高甲基化。
- IL-6、IL-15和/或MCP-1可激活STAT3并上调DNMT1、EZH2等表观调控因子。
- DNMT抑制剂阿扎胞苷经恢复SHP1表达抑制STAT3突变LGLL细胞STAT3激活。
核心结论
- STAT3突变导致DNA高甲基化,使LGLL细胞对DNMT抑制剂敏感。
研究设计与样本
- 研究比较STAT3突变LGLL患者来源CD8+ T细胞、健康CD8+ T细胞细胞因子处理及过表达STAT3突变体的KAI3 NK细胞。
主要发现
- STAT3突变LGLL患者CD8+ T细胞高表达DNMT1并呈整体高甲基化。
- IL-6、IL-15和/或MCP-1处理健康CD8+ T细胞导致STAT3激活、DNMT1/EZH2/c-MYC/l-MYC/MAX/NFκB水平升高、DNA甲基化增加及氧化应激增加。
- 过表达STAT3Y640F和STAT3G618R的KAI3 NK细胞较过表达STAT3WT的KAI3 NK细胞出现类似结果。
- STAT3与DNMT1、EZH2和HDAC1形成直接复合物。
- 阿扎胞苷通过恢复SHP1表达抑制STAT3突变LGLL细胞中STAT3激活。
临床怎么用
- DNMT抑制剂阿扎胞苷可考虑作为对标准治疗耐药的LGLL患者的新治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Large granular lymphocyte leukemia (LGLL) is characterized by somatic gain-of-function STAT3 mutations. However, the functional effects of STAT3 mutations on primary LGLL cells have not been studied in detail. In this study, we show that CD8+ T cells isolated from STAT3 mutated LGLL patients have high protein levels of epigenetic regulators, such as DNMT1, and are characterized by global hypermethylation. Correspondingly, treatment of healthy CD8+ T cells with IL-6, IL-15, and/or MCP-1 cytokines resulted in STAT3 activation, increased DNMT1, EZH2, c-MYC, l-MYC, MAX, and NFκB levels, increased DNA methylation, and increased oxidative stress. Similar results were discovered in KAI3 NK cells overexpressing gain-of-function STAT3Y640F and STAT3G618R mutants compared to KAI3 NK cells overexpressing STAT3WT. Our results also confirm that STAT3 forms a direct complex with DNMT1, EZH2, and HDAC1. In STAT3 mutated LGLL cells, DNA methyltransferase (DNMT) inhibitor azacitidine abrogated the activation of STAT3 via restored SHP1 expression. In conclusion, STAT3 mutations cause DNA hypermethylation resulting in sensitivity to DNMT inhibitors, which could be considered as a novel treatment option for LGLL patients with resistance to standard treatments.
引用
- Kim D, Park G, Huuhtanen J, et al. STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia. 2021. PMID: 34075200. doi:10.1038/s41375-021-01296-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。